Copyright © Inderes 2011 - present. All rights reserved.
  • Latest
  • Markets
    • Stock Comparison
    • Financial Calendar
    • Dividends Calendar
    • Research
    • Articles
  • inderesTV
  • Forum
  • About Us
    • Our Coverage
    • Team
Third party research

Magle Chemoswed: Delivering healthy sales - VH Corp

Magle Chemoswed Holding

This is a third party research report and does not necessarily reflect our views or values

Download report (PDF)
* Strong net sales in Q2 due to high CDMO sales and royalties
* Impressive margins mean two out of three financial targets are met
* We maintain our valuation interval SEK 46.60 – 62.80 SEK per share

Magle Chemoswed’s report for Q2 2022 showcased higher-than-expected revenue as
CDMO sales and royalties came in strong. Generic API sales have recovered well
from the temporary dip in the previous quarter and are currently back to
historic levels. This resulted in strong margins and a healthy bottom line.
During the quarter, the DSM products have developed well with sales of
EmboCept S going according to plan and manufacturing having begun for both
SmartGel and SmartPan. With two out of three financial targets fulfilled
during Q2, we keep our long-term scenario intact and therefore maintain our
valuation interval.
Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • X (Twitter)
Get in touch
  • info@hcandersencapital.dk
  • Bredgade 23B, 2. sal
    1260 København K
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Terms of service
  • Privacy policy
  • Disclaimer
Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.